• Record revenue growth of 171% to $12.6m for H1 FY25
• Achieving positive operating cash flow of $3.0m and positive EBITDA of $3.7m
• First company licensed by TGA in Australia to manufacture Psilocybin & MDMA products

Bioxyne Ltd (ASX:BXN) has reported a strong set of H1 FY25 results, with record revenue growth of 171% to $12.6m compared to the prior corresponding period. The company achieved positive operating cash flow of $3.0m and positive EBITDA of $3.7m, marking a significant turnaround from the $12.1m EBITDA loss in H1 FY24. Bioxyne has also become the first company licensed by the Therapeutic Goods Administration (TGA) in Australia to manufacture medicinal cannabis products, as well as psilocybin and MDMA products. The company has diversified its core healthcare and wellness revenue streams, from supplements to psychedelic medicines, and has executed multiple supply agreements with leading cannabis suppliers, estimated to generate $50m in sales across 2 years. Bioxyne's capital-light, high-margin business model is focused on building enduring IP and brands, and the company is well-positioned to capitalize on the growing Australian cannabis market, currently valued at an estimated ~$1bn per year.

Bioxyne has guided for minimum revenue of $25.0m for FY25.

Bioxyne is focused on exceeding its revenue guidance of $25m for FY25, executing new high-value manufacture and supply contracts, increasing investment in sales and marketing in Australia, the UK and Europe, and continuing to bolster and optimize its Australian manufacturing capacity. The company is also fast-tracking the build-out of its facility in Czechia to facilitate European and UK-based demand, and actively assessing acquisition opportunities to strengthen its competitive advantage in both domestic and international markets.